Three clinical studies are testing newer ways to control gout in adults whose allopurinol is not enough, who still experience flares, or who have visible tophi. All study-related care is provided at no cost, participants may be compensated for their time and travel, and finding out if one may be a fit takes about three minutes.
Privacy protected
HIPAA-aligned & secure data handling protocols.
No insurance required
All study-related care and medication are provided at no cost.
Three clinical studies are testing newer ways to control gout in adults whose allopurinol is not enough, who still experience flares, or who have visible tophi. All study-related care is provided at no cost, participants may be compensated for their time and travel, and finding out if one may be a fit takes about three minutes.
Each study is designed for a specific kind of gout patient. Your answers route you to the one (or more) you may qualify for.
For adults whose uric acid is still high and who have had 2+ flares in the past year despite stable allopurinol.
For adults with one or more visible tophi (chalky lumps) on hands, wrists, feet or ankles, on stable allopurinol.
For adults whose gout hasn't responded to oral medicines, or who can't take them, and have tophi, frequent flares, or chronic gouty arthritis. Compares two ways of giving pegloticase, both with weekly methotrexate.
These are the broad strokes shared across the studies. The 10-question screener confirms which specific study (if any) is right for you.
Most studies require ≥1 year since diagnosis; PEG-PRO has no minimum.
Either flares continue, uric acid stays elevated, or tophi remain visible despite treatment.
No recent major cardiovascular events. Kidney and liver function within study limits.
Required for PEG-PRO specifically; other studies have separate BMI requirements (18.5-46).
Hospitalization for heart failure, heart attack, unstable angina, stroke or DVT in the past 3-12 months.
Currently on azathioprine, mycophenolate, cyclosporine, or prednisone ≥10 mg daily for ≥3 months.
Excludes PEG-PRO; previous Dotinurad participation excludes CRYS-301 and CRYS-302.
Pregnant, breastfeeding, or planning to become pregnant.
Every study listed on this network follows established clinical research and safety standards.
Crystalys Therapeutics and Horizon Therapeutics are regulated biopharma companies running clinical trials worldwide.
Each study runs under an FDA-approved IND and is registered on ClinicalTrials.gov before enrollment opens.
An external review ensures the study is appropriate and that participant rights are protected.
Conducted at clinical research centers staffed by trained medical professionals experienced in clinical studies.
Taking part is voluntary. You may withdraw at any time without penalty or loss of benefits to which you are otherwise entitled.
DecenTrialz securely handles your information during the pre-screening process. Your data is kept confidential and managed in accordance with applicable privacy regulations.
Takes about 3 minutes. No medical records needed, no commitment. If your answers suggest you may qualify, a coordinator will follow up within 3 working days.
Used only to follow up about potential study matches.
HIPAA-aligned handling of your information.
A trained coordinator reviews your potential match.
+1Every study on this network follows established clinical research and safety standards.
TODAY · 2 MINUTES
Answer 10 short questions on this page. If your answers suggest you may be eligible, a coordinator will reach out within 3 business days for a no-obligation phone call to confirm 15 additional details.
TODAY · 2 MINUTES
Answer 10 short questions on this page. If your answers suggest you may be eligible, a coordinator will reach out within 3 business days for a no-obligation phone call to confirm 15 additional details.
WEEKS 1-5 · 1-2 SITE VISITS
Visit a nearby study site for a thorough health review: blood tests including uric acid, physical exam, ECG, and verification of medical history. All study-related costs are covered.
WEEKS 1-5 · 1-2 SITE VISITS
Visit a nearby study site for a thorough health review: blood tests including uric acid, physical exam, ECG, and verification of medical history. All study-related costs are covered.
MONTHS 2-14 · REGULAR VISITS
You receive the study medication on the schedule defined by your study: oral daily (CRYS-301/302) or subcutaneous or IV pegloticase with weekly oral methotrexate (AMG-PEG). Visit frequency drops over time. Daily diary entries via a mobile app.
MONTHS 2-14 · REGULAR VISITS
You receive the study medication on the schedule defined by your study: oral daily (CRYS-301/302) or subcutaneous or IV pegloticase with weekly oral methotrexate (AMG-PEG). Visit frequency drops over time. Daily diary entries via a mobile app.
FINAL MONTH · 1-2 FOLLOW-UPS
30 days after your last dose, the team checks in by phone. A final safety visit at the clinic wraps things up. Then you're done, with the option to discuss next-step care with your own doctor.
FINAL MONTH · 1-2 FOLLOW-UPS
30 days after your last dose, the team checks in by phone. A final safety visit at the clinic wraps things up. Then you're done, with the option to discuss next-step care with your own doctor.
DecentTrialz helps you discover clinical trials that fit your condition, location, and needs without the guesswork. We combine smart technology with real human support so you can understand your options, check eligibility, and take the next step with confidence. No medical jargon. No endless searching. Just a clear path forward.
We match you with studies based on your health, location, and preferences.
Answer a few simple questions to quickly see if a trial may be right for you.
Our registered nurses are here to guide you, answer questions, and support you throughout.
Every trial is verified with clear information and secure, compliant communication.
No commitment. No medical records needed. Just ten short questions to see if one of the three studies could change how you manage your gout.
The questions people ask us most, answered in plain language.
There are three gout clinical trials currently enrolling on this page. To see if you may qualify, take the short eligibility check above. If your answers suggest you may be a fit, a registered nurse will call you within 3 business days to connect you with the closest participating site.
Two medications are being studied across the three trials. CRYS-301 and CRYS-302 are Phase 3 trials evaluating dotinurad, an oral medication for gout. CRYS-301 is for adults whose gout flares continue on stable allopurinol. CRYS-302 is for adults with visible tophi (chalky lumps under the skin) on stable allopurinol. AMG-PEG is a Phase 3 trial evaluating pegloticase, a medication for severe gout that hasn't responded to standard pills. It compares two ways of giving pegloticase: as a subcutaneous (under-the-skin) injection or as an intravenous (IV) infusion. All participants in AMG-PEG also receive weekly oral methotrexate.
All three studies are for adults 18 and older with a confirmed gout diagnosis whose gout isn't fully controlled. Each study looks for a slightly different group: adults whose flares continue on stable allopurinol, adults with visible tophi on stable allopurinol, and adults with severe gout that hasn't responded to standard pills or who can't take them. The short eligibility check above will help identify which study (if any) may be a fit for you.
No, health insurance is not required. The sponsor covers all research-related expenses for these studies, including medications, exams, and tests. Compensation for time and travel is provided.
These trials run under FDA-reviewed protocols and are overseen by an independent ethics committee that protects participant rights. Before you join, the research team explains all known risks during the informed consent process. Side effects are possible, and you can leave the study at any time.
